Payar Radfar
Overview
Explore the profile of Payar Radfar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radfar P
Trends Biotechnol
. 2025 Feb;
PMID: 39986970
Commercialising biotechnology innovations relies on selecting an appropriate business model. This article explores the nuances of the business-to-business and business-to-consumer pathways, highlighting key considerations for selecting the best model. It...
2.
Ding L, Oh S, Shrestha J, Lam A, Wang Y, Radfar P, et al.
Biotechnol Adv
. 2023 Oct;
69:108271.
PMID: 37844769
Stem cells are specialised cells characterised by their unique ability to both self-renew and transform into a wide array of specialised cell types. The widespread interest in stem cells for...
3.
Radfar P, Ding L, Aboulkheyr Es H, Warkiani M
Methods Mol Biol
. 2023 Jun;
2679:141-150.
PMID: 37300613
The emergence of enabling technologies for the analysis of circulating tumor cells has been shedding new lights into cancer management in the recent years. However, majority of the technologies developed...
4.
Radfar P, Ding L, Rodriguez de la Fuente L, Aboulkheyr H, Gallego-Ortega D, Warkiani M
Biosens Bioelectron
. 2022 Dec;
223:114966.
PMID: 36580816
Effective isolation and in-depth analysis of Circulating Tumour Cells (CTCs) are greatly needed in diagnosis, prognosis and monitoring of the therapeutic response of cancer patients but have not been completely...
5.
Sadeghirad H, Bahrami T, Layeghi S, Yousefi H, Rezaei M, Hosseini-Fard S, et al.
Immunology
. 2022 Aug;
168(2):256-272.
PMID: 35933597
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results...
6.
Sadeghi Rad H, Shiravand Y, Radfar P, Ladwa R, Perry C, Han X, et al.
Clin Transl Immunology
. 2022 Jun;
11(6):e1397.
PMID: 35686027
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective...
7.
Radfar P, Aboulkheyr Es H, Salomon R, Kulasinghe A, Ramalingam N, Sarafraz-Yazdi E, et al.
Trends Biotechnol
. 2022 Mar;
40(9):1041-1060.
PMID: 35311650
Multimodal analysis of circulating tumour cells (CTCs) has the potential to provide remarkable insight for cancer development and metastasis. CTCs and CTC clusters investigation using single-cell analysis, enables researchers to...
8.
Morshedi Rad D, Rezaei M, Radfar P, Warkiani M
Sci Rep
. 2022 Mar;
12(1):4383.
PMID: 35288628
Intracellular delivery of nanomaterials into the cells of interest has enabled cell manipulation for numerous applications ranging from cell-based therapies to biomedical research. To date, different carriers or membrane poration-based...
9.
Herath S, Sadeghi Rad H, Radfar P, Ladwa R, Warkiani M, OByrne K, et al.
Front Oncol
. 2022 Feb;
11:801269.
PMID: 35127511
Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early diagnosis is crucial for the management and treatment of this disease. Non-invasive means of determining tumour...
10.
Sadeghi Rad H, Rad H, Shiravand Y, Radfar P, Arpon D, Warkiani M, et al.
Lung Cancer
. 2021 Jul;
159:34-41.
PMID: 34304051
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients,...